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Background: Omalizumab is a monoclonal antibody, indicated for the treatment of severe   allergic 
asthma. In Europe, there have been concerns about the cardiovascular safety of   omalizumab. The 
objective of this study was to analyze the association between omalizumab and arterial thrombotic 
events in a spontaneous adverse drug reaction reporting database in the US.
Methods and materials: Reports of arterial thrombotic events submitted to the US Food and 
Drug Administration’s Adverse Event Reporting System (AERS) between 2004 and 2011 were 
retrieved and analyzed by the reporting odds ratio data mining algorithm. The reporting odds ratio 
of arterial thrombotic events for omalizumab was compared with specific asthma medications 
and all drugs in the AERS. Values $2 were considered significant safety signals. The Medical 
Dictionary for Regulatory Activities Preferred Terms were used to identify arterial thrombotic 
events (eg, stroke, myocardial infarction).
Results: In total, 293,783 reports of arterial thrombotic events were retrieved (about 2% of 
all adverse drug reaction reports), corresponding to 2274 asthma drug-arterial thrombotic 
events pairs (omalizumab, 222; inhaled corticosteroids [ICS], 131; long-acting beta-agonists 
[LABA], 102; single-device combination ICS-LABA, 506; inhaled short-acting beta-agonists 
[SABA], 475; oral SABA, 6; inhaled antimuscarinics [AMC], 477; single-device combination 
AMC-SABA, 127; xanthines, 50; leukotriene modifiers, 174; and mast cell stabilizers, 4). 
Reporting odds ratio and 95% confidence interval values for omalizumab compared with other 
asthma drugs and all drugs in AERS were 2.75 (2.39–316) and 1.09 (0.95–1.24), respectively. 
  Omalizumab ranked second after ICS in the risk of arterial thrombotic events, followed by 
AMC, AMC-SABA, and ICS-LABA.
Conclusion: Omalizumab is associated with higher than expected reporting of arterial throm-
botic events in asthmatic patients. This hypothesis needs further testing in robust epidemiologi-
cal studies.
Keywords: omalizumab, postmarketing safety surveillance, adverse event reporting system, 
arterial thrombotic events
Introduction
Omalizumab is a monoclonal antibody that blocks immunoglobulin E, thereby 
inhibiting the early and late inflammatory reactions of asthma.1 On June 20, 2003, 
omalizumab (Xolair®; Genentech Inc, San Francisco, CA) was approved by the US 
Food and Drug Administration (FDA) for the treatment of severe persistent allergic 
asthma refractory to standard treatment.2 The drug is available in 75 mg and 150 mg 
powder and a solvent for injection, which is administered subcutaneously to patients 
aged 6 years or older, and the dose can be repeated every 2–4 weeks.3
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In February 2011, the UK Medicines and Healthcare 
  Products Regulatory Agency advised prescribers to be vigilant 
about the possible occurrence of arterial thrombotic events 
in patients exposed to omalizumab, and to report suspected 
relevant adverse reactions to the UK spontaneous adverse 
event reporting system (ie, the Yellow Card Scheme).4,5 
These recommendations were based on interim analyses of 
randomized clinical trials and an unpublished cohort study, 
ie, EXCELS (Evaluating Clinical Effectiveness and Long-
Term Safety in patients with Moderate-to-Severe Asthma).4,6 
These analyses yielded a statistically insignificant increase 
in the risk of arterial thrombotic events in groups exposed to 
omalizumab compared with their unexposed control counter-
parts (randomized clinical trials: hazard ratio [HR] 1.86, 95% 
confidence interval [CI] 0.73–4.72); EXCELS: HR 1.11, 95% 
CI 0.70–1.76).4,6 The FDA reviewed the reported adverse 
events for omalizumab in July 2009, and concluded with a 
warning to prescribers and patients about hypersensitivity 
reactions, with no reference to any arteriothrombotic risks.7 
This study assessed the safety profile of omalizumab with 
respect to arterial thrombotic events recorded in the FDA 
Adverse Event Reporting System (AERS) database.
Methods and materials
Data source
Adverse event reports recorded in FDA AERS from January 1, 
2004 to January 1, 2011 were downloaded from the FDA 
website (www.fda.gov).8 The AERS contains reports of 
adverse drug events spontaneously submitted by physicians, 
pharmacists, other health care professionals, manufacturers, 
and consumers from the US and other countries. The Medical 
Dictionary for Regulatory Activities (MedDRA) Preferred 
Terms were used to codify the adverse events. Reports for 
the same patient but from different reporting sources (dupli-
cate reports) were identified and excluded from the analysis. 
The structure of the AERS database is described elsewhere.9
identifying omalizumab and other  
asthma drugs
Omalizumab and other asthma drugs were identified by their 
nonproprietary and brand names, which in most cases were 
recorded verbatim from individual adverse event reports 
(Table 1). In addition to omalizumab, identified classes of 
asthma drugs included: inhaled corticosteroids (ICS); long-
acting beta-agonists (LABA); single-device combination ICS-
LABA; inhaled short-acting beta-agonists (SABA); orally 
administered SABA; inhaled antimuscarinics (AMC); single-
device combination SABA-AMC; oral xanthines; leukotriene 
modifiers; and mast cell stabilizers. In order to maximize the 
accuracy of capturing all the exposures of interest, the drug 
variable column of the AERS dataset was manually mined to 
extract the exposures of interest. The Clinical Pharmacology 
web-based reference tool (www.clinicalpharmacology.com)10 
is used to verify the names of the reported products in the 
drug variable whenever the recorded names are confusing or 
unclear, which was the case for a few reports (3.2%). Similarly, 
the drug name was crossreferenced with the corresponding 
indication variable column for the relevant report to look for 
asthma, chronic obstructive pulmonary disease, or respiratory-
related clinical indications, whenever reported. Reports for 
drugs with other indications, unspecified or missing drug 
names, intravenously administered xanthines, and intranasally 
and ophthalmic administered corticosteroids and mast cell 
stabilizers, are excluded from the analysis.
identifying arterial thrombotic events
Clinical judgment was applied to identify arterial throm-
botic events, which were defined by the MedDRA Preferred 
Terms codes classified under the terms listed in Table 2. 
Table 1 Identified asthma drugs
Drug class Individual agent Product example*
Monoclonal 
immunoglobulin  
E antibody
Omalizumab Xolair
iCS Beclomethasone 
Budesonide 
Fluticasone 
Mometasone
Beclovent 
Pulmicort 
Flovent 
Asmanex
inhaled LABA Formoterol 
Salmeterol
Foradil 
Serevent
Single-device  
iCS-LABA
Budesonide-formoterol 
Fluticasone-salmeterol 
Mometasone-formoterol
Symbicort 
Advair 
Dulera
inhaled SABA Salbutamol (albuterol) Ventolin
Oral SABA Salbutamol (albuterol) Proventil
inhaled AMC ipratropium 
Oxitropium 
Tiotropium
Atrovent 
Oxivent 
Spiriva
Single-device  
SABA-AMC
Salbutamol-ipratropium Combivent
Oral xanthines Theophylline 
Aminophylline
Theovent 
Phyllocontin
Leukotriene 
modifiers
Montelukast 
Zafirlukast 
Zileuton
Singulair 
Accolate 
Zyflo
Mast cell  
stabilizers
Nedocromil 
Cromolyn sodium
Tilade 
intal
Note: *Product brand names are the property of their respective manufacturers.
Abbreviations:  AMC,  antimuscarinics;  iCS,  inhaled  corticosteroids;  LABA,   
long-acting beta-agonists; SABA, short-acting beta-agonists.
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A complete list of the identified codes is available upon 
request from the corresponding author. Reports with miss-
ing or unspecified adverse events were excluded from the 
study.
reporting odds ratio data mining 
algorithm
The association between asthma drugs, including omali-
zumab, and arterial thrombotic events was analyzed using 
the reporting odds ratio and corresponding 95% CI data 
mining algorithm. Reporting odds ratio values for omali-
zumab denote the ratio of the observed to expected number 
of reported arterial thrombotic events compared with other 
asthma drugs in the data set during the analysis period. 
Values ,1 indicate no exposure-event associations; esti-
mates .1 depict exposure-event safety signals. From the 
regulatory science perspective, safety signals are considered 
significant when the reporting odds ratio estimates and the 
lower limits of the corresponding 95% CI are $2.11
Data analysis
Table 3 depicts the data mining algorithm to calculate the 
point estimates and the corresponding 95% CI for omali-
zumab, which was applied for all other asthma drugs in 
the study. Data management and analyses were performed 
using SAS software for Windows (version 9.3; SAS Institute 
Inc, Cary, NC). The tables and figures were generated by 
Microsoft Office Word software (Microsoft Corporation, 
Redmond, WA). Statistical significance tests were conducted 
at the alpha = 5% level.
Results
Overview of reports
From January 2004 to January 2011, 15,519,543 adverse 
event reports were recorded in the AERS; about 2% involved 
asthma drugs (280,857), and an additional 2% involved 
arterial thrombotic events (293,782), corresponding to 
2274 asthma drug-arterial thrombotic event pairs, with 222 
(10%) reports concerning omalizumab. Omalizumab ranked 
fourth in the number of arterial thrombotic event reports for 
asthma drugs, preceded by ICS-LABA, inhaled SABA, and 
AMC (Figure 1). Table 4 shows the distribution of identi-
fied specific arterial thrombotic events for asthma drugs. 
Myocardial infarction and stroke accounted for 29% and 
27% of the arterial thrombotic event reports for omalizumab, 
respectively. Except for orally administered SABA and leu-
kotriene modifiers, myocardial infarction contributed to the 
majority of the arterial thrombotic event reports for asthma 
drugs. The ranking distribution of the arterial thrombotic 
event categories was semihomogenous across the majority of 
asthma drug classes. Single-device combination ICS-LABA 
contributed to the majority of reports for angina, stroke, 
and cardiovascular death. Inhaled SABA contributed to the 
majority of reports for myocardial infarction, acute coronary 
syndrome, ischemic heart disease, and thrombosis. Among 
the exposure groups, omalizumab ranked third in cardiovas-
cular death category; fourth in angina, myocardial infarction, 
acute coronary syndrome, and stroke categories; and fifth in 
ischemic heart disease and thrombosis categories.
Serious arterial thrombotic events
A serious adverse event is any unwanted medical incident 
associated with exposure to a medicinal product that, at any 
dose: results in patient death; is life-threatening; requires 
inpatient hospitalization or prolongs existing hospitalization; 
results in persistent or significant disability or incapacity; or is 
a congenital anomaly or birth defect.12 Overall, there were 1055 
serious outcomes for all asthma drugs in AERS. Table 5 lists 
the distribution of serious arterial thrombotic event outcomes 
for asthma drugs. Arterial thrombotic events that required hos-
pitalization after exposure to omalizumab accounted for 42% 
of all the serious arterial thrombotic event outcomes. About 
16% of these serious events were attributed to mortality. Except 
for single-device combination ICS-LABA and xanthines, hos-
pitalization accounted for the vast majority of serious arterial 
thrombotic event outcomes for asthma drugs. Single-device 
Table 2 Selected MedDRA Preferred Terms that reflect arterial 
thrombotic events
MedDRA Preferred Terms category*
Acute coronary syndrome Stroke
Angina Thrombosis
ischemic heart disease Cardiovascular death
Myocardial infarction
Note: *Each term category has multiple verbatim terms identified. 
Abbreviation: MedDrA, Medical Dictionary for regulatory Activities.
Table 3 Reporting odds ratio and 95% confidence interval data 
mining algorithm for omalizumab
Exposure ATE Other ADR Total
Omalizumab A B A+B
Other asthma drugs C D C+D
Total A+C B+D N
rOr
AD
CB
95% Ci e
ln(rOr)1 .96
1
A
1
B
1
C
1
D =
×
×
=
±+ ++ 
 

 
Abbreviations: ATE, arteriothrombotic events; ADr, adverse drug reactions; Ci, 
confidence interval; ROR, reporting odds ratio.
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combination ICS-LABA contributed to the majority of the 
mortality,   life-threatening, and other unspecified serious arterial 
thrombotic event outcomes. Inhaled AMC contributed to the 
majority of serious disability and hospitalization outcomes. On 
the other hand, the preponderance of arterial thrombotic event 
outcomes that required intervention was for inhaled SABA. 
Compared with other asthma drugs, omalizumab ranked third 
in arterial thrombotic event outcomes that caused death, resulted 
in disability, and required hospitalization; seventh in life-
  threatening arterial thrombotic events outcomes; and second in 
other unspecified serious arterial thrombotic events outcomes.
Characteristics of arterial thrombotic 
event reports for omalizumab
Table 6 shows the characteristics of arterial thrombotic event 
reports for omalizumab. The majority of omalizumab users 
who experienced arterial thrombotic events were females 
aged $45 years. About 94% of the arterial thrombotic 
event reports were expedited reports, ie, reports for seri-
ous and unexpected events submitted by the manufacturer 
to the AERS within 15 days of occurrence.13 The product 
manufacturer is required to submit periodic reports for all 
adverse events quarterly for the first three years after prod-
uct approval, and annually thereafter over multiple years.13 
Periodic arterial thrombotic event reports for omalizumab 
accounted for 3% of the submitted arterial thrombotic event 
reports. Approximately 4% of the arterial thrombotic event 
reports were submitted directly by consumers or health 
care professionals. Fifty-five percent of the reports were 
initially submitted to the AERS, and 45% were classified 
as follow-up reports. The majority of arterial thrombotic 
event reports were received from within the US. Of the 
ICS
131 (5.76%) 
LABA
102 (4.48%) 
ICS/LABA
506 (22.2%) 
Inhaled SABA
475 (20.9%) 
Oral SABA
6 (0.26%) 
Total number of ADR reports
15,519,543 
AERS
January 1, 2004–January 1, 2011 
Omalizumab
222 (9.76%) 
Total number of ATE reports 
293,783 
AMC
477 (20.9%) 
SABA/AMC
127 (5.58%) 
Xanthines
50 (2.20%) 
LTRM
174 (7.65%) 
MCS
4 (0.17%) 
ATE reports for other drugs
291,509 
ATE reports for asthma drugs
2274 
Figure 1 Study profile.
Abbreviations: AErS, Adverse Event reporting System;8 ADr, adverse drug reactions; ATE, arteriothrombotic events; iCS, inhaled corticosteroids; LABA, long-acting 
beta-agonists; SABA, short-acting beta-agonists; AMC, antimuscarinics; LTRM, leukotriene modifiers; MCS, mast cell stabilizers.
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eight cases reporting dechallenge information, four reported 
that arterial thrombotic events did abate when omalizumab 
was stopped. Only one case reported rechallenge informa-
tion, which indicated that arterial thrombotic events did 
not relapse after reinstating omalizumab. The other reports 
stated that experimental information did not apply or was 
unknown if arterial thrombotic events terminated when 
dechallenge ensued, or recurred when rechallenge was car-
ried out. About 97% of the reports classified omalizumab as 
the primary suspect in arterial thrombotic event occurrence. 
The majority of the arterial thrombotic event reports for 
omalizumab were submitted by physicians (52%), followed 
by omalizumab users (28%). Pharmacists accounted for 2% 
of these reports, whereas 19% of the reports were submitted 
by other health care professionals such as nurses. About 80% 
of the arterial thrombotic event reports were electronically 
submitted though the MedWatch online reporting portal;14 
the remaining reports were sent via postal mail. About 94% 
of the cases reported that the patients experienced arterial 
thrombotic events more than two weeks after omalizumab 
use; only 6% of the reports stated that arterial thrombotic 
events occurred within two weeks of exposure. Although the 
majority of arterial thrombotic event reports were classified 
as expedited, 95% of the cases were reported more than two 
weeks after onset of the arterial thrombotic event. There was 
a trend of reporting arterial thrombotic event episodes for 
Table 4 Distribution of arterial thrombotic events across exposure groups
Drug Arterial thrombotic events, n (%)*
Angina MI ACS Stroke IHD THR CV death Total
Omalizumab 12 (5.4) 65 (29.3) 4 (1.8) 60 (27.0) 40 (18.0) 11 (5.0) 30 (13.5) 222
iCS 10 (7.6) 43 (32.8) 1 (0.7) 35 (26.7) 24 (18.3) 10 (7.6) 8 (6.10) 131
LABA 9 (8.8) 35 (34.3) 4 (3.9) 17 (16.7) 18 (17.6) 6 (5.9) 13 (12.7) 102
iCS-LABA 59 (11.6) 131 (25.9) 8 (1.6) 127 (25.1) 66 (13.0) 27 (5.3) 88 (17.4) 506
SABA 50 (10.5) 166 (35.0) 10 (2.1) 97 (20.4) 114 (24.0) 31 (6.5) 7 (1.4) 475
Oral SABA 2 (33.3) 2 (33.3) 0 0 0 2 (33.3) 0 6
AMC 48 (10.0) 160 (33.5) 3 (0.6) 104 (21.8) 65 (13.6) 20 (4.2) 77 (16.1) 477
SABA-AMC 4 (3.1) 43 (33.9) 0 39 (30.7) 27 (21.3) 7 (5.5) 7 (5.5) 127
Xanthines 3 (6.0) 15 (30.0) 2 (4.0) 13 (26.0) 9 (18.0) 5 (10.0) 3 (6.0) 50
Leukotriene modifiers 2 (1.1) 41 (23.5) 6 (3.4) 44 (25.3) 60 (34.4) 15 (8.6) 6 (3.4) 174
Mast cell stabilizers 1 (25.0) 2 (50.0) 0 0 0 1 (25.0) 0 4
Asthma drugs 200 (8.8) 703 (31.0) 38 (1.6) 536 (23.5) 423 (18.6) 135 (6.0) 239 (10.5) 2274
Other drugs 15,790 (5.4) 98,929 (10.7) 2554 (0.8) 76,594 (26.3) 51,859 (17.8) 26,027 (9.0) 19,756 (6.6) 291,509
Total 15,990 99,632 2592 77,130 52,282 26,162 19,995 293,783
Note: *Percentage of total arterial thrombotic events for the reported drug. 
Abbreviations: Mi, myocardial infarction; ACS, acute coronary syndrome; iCS, inhaled corticosteroids; iHD, ischemic heart disease; THr, thrombosis; CV, cardiovascular; 
AMC, antimuscarinics; iCS, inhaled corticosteroids; LABA, long-acting beta-agonists; SABA, short-acting beta-agonists.
Table 5 Distribution of serious arterial thrombotic events across exposure groups
Drug Serious arterial thrombotic events, n (%)*
Death Disability Hospital stay Life-threatening Required intervention Other§ Total
Omalizumab 30 (16.3) 10 (5.4) 78 (42.4) 1 (0.54) 0 65 (35.3) 184
iCS 8 (29) 0 10 (35.7) 2 (7.1) 1 (3.6) 7 (25) 28
LABA 13 (27) 3 (6.3) 21 (44) 2 (4.2) 0 9 (19) 48
iCS-LABA 88 (33.5) 2 (0.76) 79 (30) 11 (4.2) 1 (0.4) 82 (31.2) 263
SABA 7 (4.5) 10 (6.5) 72 (46.5) 4 (2.6) 4 (2.6) 58 (37.4) 155
Oral SABA 0 0 3 (60) 1 (20) 0 1 (20) 5
AMC 77 (29) 22 (8.3) 119 (45) 8 (3) 1 (0.4) 38 (14.3) 265
SABA-AMC 7 (16.3) 1 (2.3) 18 (42) 3 (7) 0 14 (32.6) 43
Xanthines 3 (43) 0 2 (12) 1 (6) 0 11 (65) 17
Leukotriene modifiers 6 (13) 1 (2.2) 19 (41.3) 6 (13) 0 14 (30.4) 46
Mast cell stabilizers 0 0 0 0 0 1 (100) 1
Asthma drugs 239 49 421 39 7 300 1055
Other drugs 19,756 7984 50,275 4314 816 46,379 129,524
Total 19,995 8033 50,696 4353 823 46,679 130,579
Notes: *Percentage of total serious events for the reported drug. Number of reports is mutually not exclusive, where one report could have more than one serious 
outcome classification; §unspecified serious outcomes are classified as “other”. There were only 73 reports for congenital anomalies, which were for nonasthma drugs. 
Abbreviations: AMC, antimuscarinics; iCS, inhaled corticosteroids; LABA, long-acting beta-agonists; SABA, short-acting beta-agonists.
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Table 6 Characteristics of arterial thrombotic event reports for 
omalizumab
Characteristic n (%)
Sex
  Female 104 (52)
  Male 96 (48)
Age (years)
  13–44 26 (18.8)
  45–64 57 (41.3)
  65+ 55 (39.9)
report type
  Direct 8 (3.6)
  Expedited 208 (93.7)
  Periodic 6 (2.7)
report status
  initial 122 (55)
  Follow-up 100 (45)
report source
  Domestic 119 (53.6)
  Foreign 103 (46.4)
Experimental dechallenge
  Positive result 4 (50)
  Negative result 4 (50)
Experimental rechallenge
  Negative result 1 (100)
Drug role in ATE occurrence
  Primary suspect 206 (97.2)
  Secondary suspect 6 (2.8)
reporter occupation
  Consumer 57 (27.8)
  Physician 106 (51.7)
  Pharmacist 4 (2.0)
  Other health care professional 38 (18.5)
report submission mode
  Electronic 177 (79.7)
  Mail 45 (20.3)
Time to ATE onset (days)
  0–14 7 (6.1)
  .14 107 (93.9)
Time to report ATE since onset (days)
  0–14 7 (5.0)
  .14 134 (95)
reporting year
  2004 4 (1.8)
  2005 17 (7.7)
  2006 12 (5.4)
  2007 22 (10)
  2008 19 (8.5)
  2009 74 (33.3)
  2010 74 (33.3)
Abbreviation: ATE, arteriothrombotic events.
omalizumab, which was steadily increasing, especially for 
2004–2005 and 2008–2010.
reporting odds ratio data mining 
algorithm results
Figure 2 depicts the reporting odds ratio and corresponding 
95% CI for omalizumab and other asthma drugs. Compared 
with other asthma drugs, omalizumab ranked second after ICS 
in showing a statistically significant safety signal in relation to 
arterial thrombotic events. Exposure to omalizumab was asso-
ciated with higher than expected reporting of arterial throm-
botic events (reporting odds ratio 2.75, 95% CI 2.39–3.16). 
A similar analysis was conducted using all the drugs in the 
dataset as a comparison group, including other asthma drugs, 
which yielded more conservative estimates for omalizumab, 
albeit not statistically significant (reporting odds ratio 1.09, 
95% CI 0.95–1.24). Signal dilution was ensued when all the 
drugs in the database were used as a comparator. Figure 3 illus-
trates the data mining estimates for selected arterial thrombotic 
events for omalizumab, which are calculated in comparison 
with other asthma drugs in the AERS. Cardiovascular death 
and stroke ranked first on the arterial thrombotic events list in 
detection of statistically significant safety signals (reporting 
odds ratio 3.14, 95% CI 2.14–4.56; reporting odds ratio 3.14, 
95% CI 2.41–4.05, respectively). Although the reporting odds 
ratio values for ischemic heart disease, myocardial infarction, 
and thrombosis risk exceeded 2.0, the lower limit of the 95% 
CI failed to reach that threshold, making the estimates less 
significant as safety signals (reporting odds ratio 2.63, 95% 
CI 1.92–3.63; reporting odds ratio 2.55, 95% CI 1.98–3.29; 
reporting odds ratio 2.19, 95% CI 1.18–4.01, respectively). The 
data mining algorithm did not show a statistically significant 
result for angina (reporting odds ratio 1.60, 95% CI 0.89–2.86). 
Albeit not statistically significant, the analysis showed that 
omalizumab was associated with less than expected reporting 
of acute coronary syndrome compared with other asthma drugs 
(reporting odds ratio 0.53, 95% CI 0.20–1.42).
Discussion
Adverse event reports submitted to the FDA AERS database 
from January 1, 2004 to January 1, 2011 were used to conduct 
a retrospective pharmacovigilance analysis aimed at evaluat-
ing the association of omalizumab with arterial thrombotic 
events, which yielded a statistically significant safety signal 
for the association of omalizumab with arterial thrombotic 
events relative to other asthma drugs. Myocardial infarction 
(n = 65) and stroke (n = 60) accounted for the majority of 
the omalizumab arterial thrombotic event reports. However, 
cardiovascular death and stroke events were associated with 
the strongest safety signals for omalizumab (Figure 3). These 
findings are consistent with the results from clinical trials 
and EXCELS cohort study.4,6 However, risk estimates from 
these studies were not statistically significant despite the large 
sample sizes; this could be attributed to the fact that these 
  studies were not powered to detect arterial thrombotic events 
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Figure 2 Reporting odds ratios and 95% confidence intervals for arterial thrombotic events by asthma medication classes.
Abbreviations: iCS, inhaled corticosteroids; LABA, long-acting beta-agonists; SABA, short-acting beta-agonists; AMC, antimuscarinics; LTRM, leukotriene modifiers; MCS, 
mast cell stabilizers.
as an outcome of interest.4 According to our knowledge, the 
current   pharmacovigilance analysis is the first to detect such a 
safety signal in a spontaneous adverse event reporting   database. 
However, such analysis has several limitations that are inherent 
in the nature of the data, which require consideration prior to 
drawing conclusions about such findings.   Uncertain quality of 
reported cases, missing information, variable reporting, and 
under-reporting of adverse events are common features of spon-
taneous reporting systems.   Under-reporting in   spontaneous 
reporting systems is attributed to reasons that range from mere 
ignorance of adverse event reporting requirements, the mis-
conception that only safe products are approved for marketing, 
to fear of involvement in litigation.15   Furthermore, reporting 
rates for specific adverse events or products vary over time. 
This is contingent upon the length of time the product is on 
the market, where newer products have more frequent reports, 
publicity about the product or the adverse event, marketing and 
promotion for the product, and indication or   contraindication 
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information for the product. Nevertheless, the potential for 
confounding and   misinterpretation of signals as incidence 
estimates are the most common drawbacks of pharmacovigi-
lance analyses using spontaneous reporting systems. Limited 
information about event temporality, concurrent morbidity, 
and concomitant medications introduces confounding. For 
example, risk factors that contribute to arterial thrombotic 
events occurrence are not recorded in AERS, including obesity, 
history of diabetes, hypertension, and hypercholesterolemia.16 
  Association estimates from the data mining algorithm should 
not be interpreted as incidence measures, rather more than 
expected reporting of an adverse event for a specific product. 
Therefore, the potential for Type I error when performing mul-
tiple statistical tests is high; the statistical significance of these 
findings is overestimated, and further studies are warranted to 
follow such clinically significant associations.11
Conclusion
Exposure to omalizumab is associated with an increased risk 
of arterial thrombotic events in asthmatic patients, predomi-
nantly cardiovascular death and stroke. In light of causality 
restraints of the current analysis, robust epidemiological stud-
ies are recommended to test this hypothesis further in order 
to draw conclusions that contribute to clinical practice and 
public health. Meanwhile, until such conclusions are made 
and recommendations are prepared by regulatory authori-
ties, the findings suggest that prescribers should cautiously 
prescribe omalizumab to asthmatic patients who have risk 
factors that contribute to arteriothrombotic events.
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Figure 3 Visual presentation of reporting odds ratios and 95% confidence intervals for selected arterial thrombotic events for omalizumab.
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